Novartis Competitors

Johnson & Johnson (NYSE:JNJ) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Johnson & Johnson and Novartis' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Johnson & Johnson and Novartis' top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

66.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 9.5% of Novartis shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Johnson & Johnson has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Johnson & Johnson and Novartis, as reported by MarketBeat.com.

Johnson & Johnson presently has a consensus price target of $190.3750, indicating a potential upside of 10.55%. Novartis has a consensus price target of $108.50, indicating a potential upside of 17.44%. Given Novartis' higher possible upside, analysts plainly believe Novartis is more favorable than Johnson & Johnson.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.5%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 59 consecutive years and Novartis has increased its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Johnson & Johnson beats Novartis on 15 of the 17 factors compared between the two stocks.

Novartis (NYSE:NVS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Risk and Volatility

Novartis has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Novartis and Pfizer, as provided by MarketBeat.com.

Novartis presently has a consensus price target of $108.50, suggesting a potential upside of 17.44%. Pfizer has a consensus price target of $43.0833, suggesting a potential upside of 0.64%. Given Novartis' stronger consensus rating and higher possible upside, analysts clearly believe Novartis is more favorable than Pfizer.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.6%. Novartis pays out 36.2% of its earnings in the form of a dividend. Pfizer pays out 70.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has raised its dividend for 1 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Profitability

This table compares Novartis and Pfizer's net margins, return on equity and return on assets.

Insider & Institutional Ownership

9.5% of Novartis shares are held by institutional investors. Comparatively, 64.1% of Pfizer shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Novartis and Pfizer's revenue, earnings per share and valuation.

Pfizer has lower revenue, but higher earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Novartis on 9 of the 16 factors compared between the two stocks.

Novartis (NYSE:NVS) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Novartis pays out 36.2% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has raised its dividend for 1 consecutive years and Eli Lilly and has raised its dividend for 1 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Institutional & Insider Ownership

9.5% of Novartis shares are held by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Novartis and Eli Lilly and's gross revenue, earnings per share and valuation.

Novartis has higher revenue and earnings than Eli Lilly and. Novartis is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Novartis and Eli Lilly and, as reported by MarketBeat.com.

Novartis presently has a consensus price target of $108.50, indicating a potential upside of 17.44%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Novartis' higher probable upside, equities analysts plainly believe Novartis is more favorable than Eli Lilly and.

Profitability

This table compares Novartis and Eli Lilly and's net margins, return on equity and return on assets.

Volatility & Risk

Novartis has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Novartis on 11 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Volatility & Risk

Novo Nordisk A/S has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Institutional & Insider Ownership

5.6% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 9.5% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.4%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has raised its dividend for 1 consecutive years and Novartis has raised its dividend for 1 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Novo Nordisk A/S and Novartis' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Novo Nordisk A/S and Novartis' gross revenue, earnings per share (EPS) and valuation.

Novartis has higher revenue and earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Novo Nordisk A/S and Novartis, as provided by MarketBeat.

Novartis has a consensus price target of $108.50, indicating a potential upside of 17.44%. Given Novartis' stronger consensus rating and higher probable upside, analysts plainly believe Novartis is more favorable than Novo Nordisk A/S.

Summary

Novartis beats Novo Nordisk A/S on 10 of the 16 factors compared between the two stocks.

Novartis (NYSE:NVS) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

Institutional and Insider Ownership

9.5% of Novartis shares are held by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 1.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Novartis and Abbott Laboratories, as reported by MarketBeat.com.

Novartis presently has a consensus target price of $108.50, indicating a potential upside of 17.44%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Novartis' higher possible upside, analysts clearly believe Novartis is more favorable than Abbott Laboratories.

Profitability

This table compares Novartis and Abbott Laboratories' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Novartis and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Novartis has higher revenue and earnings than Abbott Laboratories. Novartis is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novartis has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Novartis pays out 36.2% of its earnings in the form of a dividend. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 49 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Abbott Laboratories beats Novartis on 10 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for AbbVie and Novartis, as provided by MarketBeat.com.

AbbVie presently has a consensus target price of $121.6733, suggesting a potential upside of 4.62%. Novartis has a consensus target price of $108.50, suggesting a potential upside of 17.44%. Given Novartis' higher probable upside, analysts plainly believe Novartis is more favorable than AbbVie.

Profitability

This table compares AbbVie and Novartis' net margins, return on equity and return on assets.

Insider & Institutional Ownership

66.0% of AbbVie shares are owned by institutional investors. Comparatively, 9.5% of Novartis shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Novartis has raised its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings and Valuation

This table compares AbbVie and Novartis' top-line revenue, earnings per share and valuation.

Novartis has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AbbVie has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Summary

AbbVie beats Novartis on 12 of the 17 factors compared between the two stocks.